Search results for "MDM"

showing 3 items of 93 documents

Enantioselective determination of plasma protein binding of common amphetamine-type stimulants.

2021

Amphetamine-type stimulants (ATS) like amphetamine ('speed'), methamphetamine ('crystal meth') and 3,4-methylenedioxy-N-methylamphetamine (MDMA, 'ecstasy') represent some of the most frequently abused drugs worldwide. Another less frequently abused ATS is 4-fluoroamphetamine (4-FA). The enantiomers of these four compounds exhibit different pharmacokinetic and pharmacodynamic properties. According to the free drug theory, the pharmacological properties of a substance are dependent on its plasma protein binding (PPB). However, data on PPB of stimulant enantiomers in humans are rare or non-existent. Human plasma samples were spiked with racemic mixtures of the stimulants and subjected to ultra…

medicine.medical_treatmentClinical BiochemistryPharmaceutical ScienceTandem mass spectrometryAnalytical ChemistryPharmacokineticsTandem Mass SpectrometryDrug DiscoverymedicineHumansAmphetamineSpectroscopyChromatographyChemistryIllicit DrugsForensic toxicologyMDMAStereoisomerismMethamphetamineStimulantAmphetamineCentral Nervous System StimulantsEnantiomermedicine.drugChromatography LiquidProtein BindingJournal of pharmaceutical and biomedical analysis
researchProduct

Molecular mechanisms of MYCN-dependent apoptosis and the MDM2-p53 pathway: an Achille’s heel to be exploited for the therapy of MYCN amplified neurob…

2012

The p53 oncosuppressor is very seldom mutated in neuroblastoma, but several mecha- nisms cooperate to its functional inactivation in this tumor. Increased MDM2 levels, due to genetic amplification or constitutive inhibition of p14ARF, significantly contribute to this event highlighting p53 reactivation as an attractive perspective for neuroblastoma treat- ment. In addition to its role in tumorigenesis, MYCN sensitizes untransformed and cancer cells to apoptosis. This is associated to a fine modulation of the MDM2-p53 pathway Indeed MYCN induces p53 and MDM2 transcription, and, by evoking a DNA damage response (DDR), it stabilizes p53 and its proapoptotic kinase Homeodomain Interacting Prote…

p53Programmed cell deathCancer ResearchHMGA1HIPK2Biologymedicine.disease_causelcsh:RC254-28203 medical and health sciencesNeuroblastoma0302 clinical medicineMDM2NeuroblastomaMYCNmedicineProtein kinase Aneoplasms030304 developmental biology0303 health sciencesKinaseHMGA1amedicine.diseaselcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensHMGA13. Good healthOncology030220 oncology & carcinogenesisCancer cellPerspective ArticleMDM2-antagonistsbiology.proteinCancer researchMdm2CarcinogenesisMDM2-antagonistFrontiers in Oncology
researchProduct

Design, Synthesis, Chemical and Biochemical Insights Into Novel Hybrid Spirooxindole-Based p53-MDM2 Inhibitors With Potential Bcl2 Signaling Attenuat…

2021

The tumor resistance to p53 activators posed a clinical challenge. Combination studies disclosed that concomitant administration of Bcl2 inhibitors can sensitize the tumor cells and induce apoptosis. In this study, we utilized a rapid synthetic route to synthesize two novel hybrid spirooxindole-based p53-MDM2 inhibitors endowed with Bcl2 signaling attenuation. The adducts mimic the thematic features of the chemically stable potent spiro [3H-indole-3,2′-pyrrolidin]-2(1H)-ones p53-MDM2 inhibitors, while installing a pyrrole ring via a carbonyl spacer inspired by the natural marine or synthetic products that efficiently inhibit Bcl2 family functions. A chemical insight into the two synthesized…

p53human homolog of mouse double minute 2 (MDM2)ChemistryGeneral ChemistryspirooxindoleBcl 2protein–protein interaction (PPI)QD1-999Original ResearchFrontiers in Chemistry
researchProduct